# Metastatic non-small cell lung cancer with BRCA2 mutation—a therapeutic challenge

## TL;DR

A patient with lung cancer and a BRCA2 mutation had poor outcomes with PARP inhibitor therapy, suggesting more research is needed for effective treatments.

## Contribution

This case study explores the therapeutic challenge of BRCA2-mutated non-small cell lung cancer and highlights the need for further research.

## Key findings

- The patient with BRCA2-mutated lung cancer did not respond to second-line Olaparib therapy.
- BRCA mutations in non-small cell lung cancer are rare but may represent a potential therapeutic target.
- Further large-scale studies are needed to improve treatment outcomes for BRCA-mutated NSCLC.

## Abstract

Non-small cell lung cancer, specifically adenocarcinoma, is amenable to targeted therapy for genetic alterations. The role of BRCA mutations in pathogenesis and the efficacy of PARP inhibitors in these cases are still unclear. This case involves a 61-year-old male patient with a past history of Hodgkin’s Lymphoma and a heavy smoking history who developed lung adenocarcinoma and was found to have a BRCA2 mutation. Following disease progression on first-line chemotherapy and a detailed case discussion in the multidisciplinary team meeting, second-line Olaparib was started, but the patient's condition worsened rapidly, and he died from the illness. This case highlights the fact that BRCA mutations, though less common, are a potential target that should be explored further. Further large-scale studies are crucial to understanding and improving treatment outcomes for patients with BRCA-mutated NSCLC.